<div class="white-sheet">
	<div class="content-slide">


		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-8">


			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title red two-line">
				Risk of cytogenetic abnormalities and progression <br />to clonal disorders
			</div>


			<div class="content-container">

				<ul>
					<li><span>TPO-R agonists may stimulate development of dysplastic or leukaemic stem cells by triggering the development of cytogenetic abnormalities in bone marrow cells<sup>1</sup></span></li>
					<li><span>Cytogenetic abnormalities are a known long-term risk in patients with SAA, and may lead to disorders such as MDS and leukaemia<sup>2</sup></span>
						<ul>
							<li><span>Cytogenetic abnormalities have been reported in 15–20% of patients with SAA<sup>3</sup></span></li>
						</ul>
					</li>
					<li><span>Three patients (7%) included in the study had cytogenetic abnormalities at baseline<sup>3</sup></span></li>
					<li><span>Eight patients (19%) developed cytogenetic abnormalities after eltrombopag treatment<sup>4</sup></span>
						<ul>
							<li><span>Six patients were non-responders</span></li>
							<li><span>Five patients had chromosome 7 abnormalities</span></li>
							<li><span>Two patients had trisomy 8 and deletion of chromosome 13<sup>3</sup></span></li>
						</ul>
					</li>
					<li><span>Three patients were diagnosed with MDS after eltrombopag treatment<sup>3</sup></span>
						<ul>
							<li><span>Two patients received HSC transplantation, and one died of MDS/AML more than 6 months post therapy</span></li>
							<li><span>For further explanation on cytogenetic abnormality development, please refer to Module 2</span></li>
						</ul>
					</li>
				</ul>

			</div>

		</div>


		<div class="information-overlay overlay">

			<header>Risk of cytogenetic abnormalities and progression to clonal disorders</header>
				
			<ul>
				<li><span>Myelodysplastic syndrome arises from aneuploidy (an abnormal chromosome number), frequently monosomy 7 and trisomy 8<sup>5</sup></span></li>
				<li><span>Monosomy 7 is associated with refractory cytopenia or acute myeloid leukaemia<sup>5</sup></span></li>
				<li><span>Prognosis is poorer in patients with SAA who develop cytogenetic abnormalities compared with those who do not<sup>6</sup></span></li>
				<li><span>In patients who develop cytogenetic abnormalities, transplantation may be implemented because it is associated with a reduced risk of relapse and evolution of late clonal disorders<sup>7</sup></span></li>
				<li><span>There is no literature on the incidence of cytogenetic abnormalities in the heavily pretreated population investigated in the pivotal trial<sup>8</sup></span>
					<ul>
						<li><span>However, the 7–16% incidence of cytogenetic abnormalities in the studies of eltrombopag in SAA appears to be in agreement with published literature</span></li>
						<li><span>Given the lack of experience with continued eltrombopag treatment in the presence of a new cytogenetic abnormality, it is recommended that discontinuation of eltrombopag be considered if new cytogenetic abnormalities are observed</span></li>
					</ul>
				</li>
			</ul>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/TownsleyD-2013-IntJHematol-v98p48.pdf"><span>Townsley DM <i>et al. Int J Hematol</i> 2013;98:48</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/AfableM-2011-HASHEP-v2011p90.pdf"><span>Afable MG <i>et al. Hematology Am Soc Hematol Educ Program</i> 2011;90</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/GlaxoSmithKline-2014-DoF-ELT112523.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/DesmondR-2014-Blood-v123p1818.pdf"><span>Desmond R <i>et al. Blood</i> 2014;123:1818</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/YoungN-2008-CurrOpinHematol-v15p162.pdf"><span>Young NS <i>et al. Curr Opin Hematol</i> 2008;15:162</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/ScheinbergP-2012-Blood-v120p1185.pdf"><span>Scheinberg P & Young NS. <i>Blood</i> 2012;120:1185</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/DeZernA-2011-ExpertRevHematol-v4p221.pdf"><span>DeZern AE & Brodsky RA. <i>Exp Rev Hematol</i> 2011;4:221</span></li>
				<li class="navigateHref" data-navtarget="media/documents/module3/GlaxoSmithKline-2014-DoF-ClinicalOverview-v2.5.pdf"><span>GlaxoSmithKline. Data on File. Clinical overview module 2.5. 2014</span></li>
			</ul>

		</div>


		

	</div>
</div>